Clik here to view.
AASLD 2016: Generic Sofosbuvir Underperforms in Real World, May Be Due to...
Generic sofosbuvir-based combinations for hepatitis C may not perform as well as branded sofosbuvir-containing regimens, according to a study conducted in Qatar and presented at the recent 2016 AASLD...
View ArticleClik here to view.
AASLD 2016: Real-World Studies Show 8 Weeks of Sofosbuvir/Ledipasvir Equals...
An 8-week course of treatment with sofosbuvir/ledipasvir (Harvoni) is just as effective as a 12-week course for people with hepatitis C virus (HCV) genotype 1 without cirrhosis, including those with...
View ArticleClik here to view.
9. Primary Care Providers Can Treat Hepatitis C
Interferon-free direct-acting antiviral therapy for hepatitis C is effective and simple enough that care can be managed by primary care providers, helping relieve the shortage of liver disease...
View ArticleClik here to view.
8. More Treatment Options for More Types of HCV
This year saw the approval of new highly effective direct-acting antiviral therapies for hepatitis C, with more in the pipeline and due for approval in 2017.
View ArticleClik here to view.
Gilead and AbbVie Seek FDA Approval of Pangenotypic Hepatitis C Treatments
Gilead Sciences and AbbVie both announced this month that they have applied for U.S. Food and Drug Administration approval of new all-oral ribavirin-free combination regimens to treat all genotypes of...
View ArticleClik here to view.
CROI 2017: Glecaprevir/ Pibrentasvir for HCV Can Be Safely Administered with...
AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering...
View ArticleClik here to view.
FDA Approves Harvoni and Sovaldi for Adolescents with Hepatitis C
The U.S. Food and Drug Administration (FDA) on April 7 approved the first direct-acting antivirals for the treatment of chronic hepatitis C virus (HCV) infection in adolescents age 12 to 17 years....
View ArticleClik here to view.
EASL 2017: International Liver Congress Starts This Week in Amsterdam
The European Association for the Study of the Liver (EASL) International Liver Congress (ILC 2016) will take place April 19-23 at the RAI Centre in Amsterdam. The congress is one of the major annual...
View ArticleClik here to view.
Coverage of the 2017 Conference on Retroviruses and Opportunistic Infections
HIVandHepatitis.com coverage of the 2017 Conference on Retroviruses and Opportunistic infections (CROI 2017), February 13-16, 2017, in Seattle. HIVandHepatitis.com coverage by topic CROI website 4/16/17
View ArticleClik here to view.
EASL 2017: AbbVie Combination Cures Most People with Genotype 3 Hepatitis C
AbbVie's pangenotypic direct-acting antiviral combination of 2 drugs cured 95% of people with early-stage genotype 3 hepatitis C virus (HCV) infection, the hardest genotype to treat, according to...
View ArticleClik here to view.
EASL 2017: Children with Hepatitis C Respond Well to Sofosbuvir/Ledipasvir
Almost all children age 6 to 11 with hepatitis C who were treated with a half-strength tablet of sofosbuvir/ledipasvir were cured, which is important as some of them had advanced liver damage even at...
View ArticleClik here to view.
EASL 2017: New AbbVie Hepatitis C Combination Cures 99% of People with Cirrhosis
A new pangenotypic direct-acting antiviral combination developed by AbbVie is highly effective in curing hepatitis C in people with cirrhosis, achieving a 99% cure rate after 12 weeks of treatment...
View ArticleClik here to view.
EASL 2017: Generic Hepatitis C Drugs Continue to Produce High Cure Rates
Treatment with generic versions of direct-acting antiviral drugs (DAAs) for hepatitis C continues to produce similar cure rates to those reported in clinical trials of brand-name drugs, James Freeman...
View ArticleClik here to view.
EASL 2017: Triple Combination Cures Most Hepatitis C Patients with Prior DAA...
Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated...
View ArticleClik here to view.
HR17: Hepatitis C Virus Reinfection Is Uncommon After Being Cured with DAAs
Most people on opiate substitution therapy were successfully treated for hepatitis C with an interferon-free regimen of grazoprevir/elbasvir (Zepatier), and only a small number became reinfected...
View ArticleClik here to view.
HR17: Indonesian Buyers Club Helps People Obtain Generic Hepatitis C Treatment
A community-led buyers club in Indonesia has helped more than 100 people get generic direct-acting antiviral drugs to treat hepatitis C and is seeing a high cure rate, according to a presentation at...
View ArticleClik here to view.
Coverage of the 2017 Harm Reduction International Conference
HIVand Hepatitis.com coverage of the 2017 Harm Reduction International Conference, May 14-17, 2017, in Montreal. Full coverage listing by topic HR17 website 5/31/17
View ArticleClik here to view.
FDA Approves Gilead's Vosevi Combo Pill for Hepatitis C Re-treatment
On July 18, the U.S. Food and Drug Administration(FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as...
View ArticleClik here to view.
IAS 2017: Hepatitis C treatment is Effective and Feasible in Africa
Treatment for hepatitis C in sub-Saharan Africa can produce cure rates as high as those seen in industrialized countries, with high adherence and minimal side effects, according to a presentation this...
View ArticleClik here to view.
FDA Approves AbbVie's 8-Week Mavyret Combo Pill for Hepatitis C
On August 3 the U.S.Food and Drug Administration(FDA) approved AbbVie's new pangenotypic combination pill for people with hepatitis C virus (HCV) genotypes 1 through 6, to be marketed under the brand...
View Article